Boundless Bio develops drugs that target ecDNA—a type of DNA found outside chromosomes within cancer cells. Its unique approach involves designing therapeutics aimed at treating oncogene-amplified cancers. These are aggressive tumors that standard treatments often fail to control. The company's core focus is its Spyglass platform, which pinpoints drug targets involved in ecDNA function. Its lead program, BBI-355, targets oncogene amplification through small molecule drugs. It aims to be the first to bring e ...